Slow down on biosimilar substitution, says Australian Senate committee
This article was originally published in SRA
Executive Summary
The Australian government may have to rethink its plans for biosimilar substitution after a parliamentary committee said that concerns over safety expressed by industry, patients and health professionals needed to be addressed.